ArticleInternational journal of women's health2025
The Predictive Role of Neutrophil Percentage-to-Albumin Ratio (NPAR) in Endometrial Carcinoma: A Novel Prognostic Marker.
Article in International journal of women's health, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Symptom-Heavy Nutritional Insecurity in Older Adults Initiating Chemotherapy.Healthcare (Basel, Switzerland) · 2026Article
- Platelet-to-Lymphocyte Ratio as a Predictor of Lymphovascular Space Invasion in Endometrioid Endometrial Cancer: Development and Internal Validation of a Continuous Parameter-Based Nomogram.Medicina (Kaunas, Lithuania) · 2026Article
- Prognostic Value of Neutrophil Percentage-Albumin Ratio in Patients with Advanced Melanoma Treated with Immune Checkpoint Inhibitors.Current oncology (Toronto, Ont.) · 2026Article
- Establishment and evaluation of a novel tool based on inflammation-nutrition derived biomarkers for early diagnosis of diabetic foot ulcers.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endometrial carcinoma, EC is the most common gynecologic malignancy in developed countries, and identifying accessible prognostic markers remains critical for guiding treatment strategies. Systemic inflammatory markers have emerged as promising tools in cancer prognosis. Objective: This study aimed to investigate the predictive value of the neutrophil percentage-to-albumin ratio, NPAR in patients diagnosed with endometrial carcinoma and to compare its utility with other systemic inflammatory indices. Methods: This retrospective study included 194 patients who underwent surgical treatment for endometrial carcinoma between January 2020 and May 2025 at a tertiary care center. Preoperative blood samples were used to calculate neutrophil percentage-to-albumin ratio, NPAR, neutrophil-to-lymphocyte ratio, NLR, platelet-to-lymphocyte ratio, PLR, systemic immune-inflammation index, SII, and other related markers. Patients were analyzed according to final pathological outcomes, and the relationship between inflammatory indices and prognostic parameters such as tumor grade, histologic type, depth of myometrial invasion, lymphovascular space invasion, LVSI and FIGO stage was evaluated. Receiver operating characteristic, ROC analysis was performed to determine optimal cutoff values for NPAR. Results: NPAR did not show a statistically significant association with lymphovascular space invasion (LVSI) or deep myometrial invasion. However, it was significantly associated with advanced stage (FIGO ≥ Stage II). High NPAR, elevated SIRI, high PLR, low NLR, elevated MLR, and increased immature granulocyte count were significant predictors of advanced stage. The regression model demonstrated strong predictive ability for advanced disease (Nagelkerke Conclusion: NPAR is a novel, simple, and cost-effective prognostic biomarker in endometrial carcinoma. Its preoperative evaluation may help identify high-risk patients and contribute to more individualized treatment planning. Further prospective studies are warranted to validate these findings.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.